Welcome to our dedicated page for Cosmo Pharmaceuticals Nv news (Ticker: CMOPF), a resource for investors and traders seeking the latest updates and insights on Cosmo Pharmaceuticals Nv stock.
Cosmo Pharmaceuticals N.V. reports news across its life sciences business, including MedTech AI, dermatology, gastrointestinal disease programs, and contract development and manufacturing. Company updates frequently cover the GI Genius™ platform and real-time medical AI for endoscopy, dermatology assets such as Clascoterone 5% topical solution and Winlevi®, and gastroenterology research programs in bile acid diarrhea and distal ulcerative colitis.
Recurring disclosures also include annual results, recurring revenue trends, dividend actions, AGM voting outcomes, ESG reporting, board and remuneration matters, and capital-structure authorizations. Partnership and R&D collaboration announcements describe how Cosmo extends AI-enabled medical technology into additional clinical applications while maintaining a broader portfolio of pharmaceutical and CDMO activities.
Cosmo Pharmaceuticals N.V. invites stakeholders to a Q&A session on May 4, 2021, discussing its FDA-approved AI device, GI Genius™, designed for detecting colon cancer. This technology, also approved in Europe, Australia, Israel, and the UAE, is distributed globally through a partnership with Medtronic. Key representatives, including CEO Alessandro Della Chà and CFO Niall Donnelly, will explain how GI Genius™ addresses colorectal cancer challenges. The company focuses on gastrointestinal disorders and has partnerships for product distribution.
Cosmo Pharmaceuticals has received FDA approval for its GI Genius™ intelligent endoscopy system, a groundbreaking device designed for detecting lesions during colonoscopy. This marks a significant achievement after over a decade of research, as it is the first device of its kind to achieve approval via the De Novo application. The system operates in real-time, improving detection rates of precancerous lesions and is compatible with all endoscopes. Cosmo has partnered with Medtronic for worldwide distribution, aiming at a market potential worth at least $1.1 billion.
Cosmo Pharmaceuticals N.V. reported a return to operating profit in 2020, with revenues of €60.9 million, slightly down from €62.5 million in 2019. The company achieved a €6.9 million operating profit, compared to a €12.3 million loss the previous year. Net expenses dropped significantly to €54 million from €74.8 million. Despite a net loss after tax of €7.9 million, improved cash flow and significant equity stakes position Cosmo favorably, holding €212.9 million in cash. The 2021 outlook anticipates revenues between €60 million and €64 million, contingent on FDA approval for GI Genius™.
Cosmo Pharmaceuticals NV (SIX: COPN) will hold a telephone conference on March 26, 2021, at 2:00 PM CET to discuss its 2020 financial results and 2021 outlook. CEO Alessandro Della Chà and CFO Niall Donnelly will present during this session. Dial-in numbers are provided for participants from Switzerland, the UK, and the US. The presentation materials will be available on the company's website from 7:00 AM CET on the same day. Cosmo focuses on developing products for gastrointestinal disorders and has partnered with Medtronic for its AI device.